Adrenal Insufficiency Clinical Trial
Official title:
Hydrocortisone Versus Prednisolone for Treatment of Adrenal Insufficiency Disease (HYPER-AID Study)
This study is designed to collect data on individuals with adrenal insufficiency who are changing treatments from hydrocortisone to prednisolone, or vice versa. It will compare anthropometric, biochemical and subjective health outcomes between both treatments.
In the UK, oral immediate release hydrocortisone divided in three doses daily has been the traditional treatment. The most common regimen in clinical practice uses doses of 10 mg on waking, 5 mg at lunch time and 5 mg in the afternoon. Once daily prednisolone is another regimen in clinical use and now prescribed at less than 5mg daily. It has a longer duration of action and a smoother pharmacokinetic profile compared to hydrocortisone. Moreover, prednisolone is much more cost-effective than hydrocortisone with 5mg tablets. Prednisolone is less commonly used due to perceived concerns regarding loss of bone mineral density leading to osteoporosis, increased insulin resistance leading to steroid induced diabetes, and rises in blood pressure and weight leading to increased cardiovascular risk. This belief is perhaps driven by the fact that most clinicians encounter prednisolone in the context of the treatment of asthma, rheumatoid arthritis etc. where far higher doses are employed. Where effects on bone health have been noted, they have been in association with higher doses of prednisolone (7.5mg) than those employed today (2-5mg). Although conventionally prednisolone 5 mg is assumed to be bioequivalent to HC 20 mg (ratio 1:4), newer studies suggest that the ratio may be nearer 1:6-8 i.e. lower doses can be used. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT03282487 -
Optimising Steroid Replacement in Patients With Adrenal Insufficiency
|
Phase 4 | |
| Not yet recruiting |
NCT05716607 -
Treatment Study in Patients Treated With Both Insulin & Hydrocortisone
|
N/A | |
| Not yet recruiting |
NCT06435481 -
Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics
|
Phase 4 | |
| Recruiting |
NCT03399383 -
Adherence in Chronic Adrenal Insufficiency
|
N/A | |
| Completed |
NCT01428336 -
Value of 25 mcg Cortrosyn Stimulation Test
|
N/A | |
| Completed |
NCT00851942 -
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
|
Phase 4 | |
| Withdrawn |
NCT00368381 -
Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis
|
Phase 4 | |
| Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
| Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
| Completed |
NCT03013166 -
THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone
|
||
| Enrolling by invitation |
NCT02282150 -
Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism
|
Phase 4 | |
| Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
| Completed |
NCT03000231 -
Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency
|
||
| Completed |
NCT01960530 -
An Investigational Study of Hydrocortisone
|
Phase 1 | |
| Completed |
NCT00552487 -
Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis
|
N/A | |
| Completed |
NCT00575341 -
Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency
|
Phase 3 | |
| Completed |
NCT00471900 -
Six Months DHEA Treatment in Female Adrenal Failure
|
N/A | |
| Completed |
NCT03294876 -
Rheumatoid Arthritis Adrenal Recovery Study
|
||
| Completed |
NCT03709381 -
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
|
Early Phase 1 | |
| Recruiting |
NCT05639127 -
The Treatment of Adrenal Crisis With Inhaled Prednisolone
|
Early Phase 1 |